(NASDAQ:OPTN) OPTINOSE INC. announced positive top line results from Phase 3 clinical study.

Shares are up 23% on 1,492 trades today. $2.29 a share on almost 600k volume.

Optinose Announces Positive Top-line Results of ReOpen2, its second Phase 3 Clinical Trial of XHANCE for Treatment of Chronic Sinusitis

First Ever Phase 3 Program to Show Improvement in Both Symptoms and Inflammation Inside the Sinuses with a Nasal Therapy for Chronic Sinusitis Patients
Physicians Diagnose Chronic Sinusitis 10 Times More Frequently Than XHANCEs Current Nasal Polyps Indication and there is no FDA-Approved Medication for these Patients

Conference call and webcast to be held today at 8:30 a.m. Eastern Time

https://finance.yahoo.com/news/optinose-announces-positive-top-line-110000465.html

Signup today for free and be the first to get notified of breaking news.

SIGN UP FOR OUR NEWSLETTER

Sign up for Breaking Alerts, our newsletter putting timely and updated stock and crypto markets news into your hands.

Add New Playlist